reason report
surpris sale miss pipelin execut critic
bottom line share trade lower today driven investor
reaction surpris broad-bas sale miss compani
point transient issu specif erp upgrad within
mitg minim invas therapi group busi area
weak seem due share loss around time new product
launch deliv oper margin expans
bp y/i report bp constant currenc even sale
miss encourag help bp
expens incom line manag provid organ
sale guidanc ex impact viru
china line consensu also note post-
earn call compani expect neg impact procedur
volum delay magnitud durat impact
difficult quantifi still fluid situat clearli
manag -- specif soon-to-b ceo geoff martha --
focus implement chang intern improv quarterli
visibl avoid neg surpris go forward
manag reiter confid growth acceler
also note quarter
shake -- seemingli extent investor -- confid
consist execut ultim broad pipelin
energ manag team think piec
eventu return least in-line-with-market growth
believ time extent sale growth reacceler
much depend new product launch execut
reiter mp pt price target --
-- appli price-to-earnings multipl ep estim
assum share sustain current multipl
ep estim though believ could eventu
return path consist mid-single-digit top-lin growth time
less certain see limit multipl expans
mid-single-digit growth trajectori larg predic new
product launch sustain trend without risk
estim updat reflect result estim
sale y/i oper report ep
report vs previous
medic suppli devic
ep
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total sale
cardiac rhythm manag spine market estim grow low-
single-digit best mdt sustain growth trajectori larg predic recent
upcom new product launch
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans bp per year
major med-tech market broadli spine specif experienc real
price target appli price-to-earnings multipl ep estim
assum share sustain current multipl ep estim
though believ could eventu return path consist mid-single-digit
top-lin growth time less certain see limit multipl expans
mid-single-digit growth trajectori larg predic new product launch
sustain trend without risk
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item includ contributor visibl alpha
consensu estim
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item includ contributor visibl alpha
consensu estim
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net tax
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
revenu report
organ revenu ex fx divestitur
compani report svb leerink estim
coronaviru fx impact
neg
impact neg
impact neg
impact neg
impact neg
impact neg
impact neg
fx impact neg
sg
flat lsd
op margin
fx impact
flat sligtli
off-set fx
lower end
op margin
similar
similar
op margin
impli
ep growth
ex fx fx impact
impli
ep growth
ex fx fx impact
low- mid-teen
impli base
similar
impli
ep growth
ex fx fx impact
fx impact
impli
ep growth
ex fx fx impact
fx
impli
ep growth
midpoint ex fx
fx
greater
save
ex fx
ex fx
greater
save
ex fx
sg increas
fx posit
greater
save
ex fx
higher end
organ ex fx impact
neg fx impact
higher end
organ ex fx impact
neg fx impact
low- mid-teen
low- mid-teen
stronger
littl
impact neg
posit fx impact
closer
minu side
full year
impact fx
impact fx
minu side
full year
stronger
stronger
improv
mid high singl
mid high singl
lower half mid-singl
fx
headwind
lower half mid-singl
impact fx
sg increas
flat fx
flat
ex fx
upper end singl digit
rang fx
 one-tenth size tradit pacemak without need lead
 build upon success micra vr driven point increas unit
share point increas revenu share us singl chamber pacemak
 expand micra target popul pacemak patient drive
diamond insert thermal manag
 disrupt technolog billion ep ablat market add rf cathet
portfolio multi-billion dollar advanc focal categori
renal nerv denerv patient hypertens paroxysm
persist atrial fibril symplic af purpos clinic studi
evalu feasibl perform renal nerv denerv pulmonari vein
isol patient intent character safeti
effect paroxysm persist atrial fibril popul
hypertens assess safeti studi measur occurr composit
safeti endpoint assess effect studi measur freedom
chronic treatment failur minimum six month follow-up
marvel data present aha publish jacc clinic
electrophysiolog demonstr signific improv synchroni
cardiac function av block patient
expect us fda approv end
ce mark launch europ
us fda approv expect
estim enrol particip random
receiv fda approv begin pivot trial
global clinic studi renal denerv symplic spyral multi-
electrod renal denerv system patient uncontrol
hypertens standard medic therapi spyral htn-on
purpos studi obtain assess efficaci safeti
renal denerv presenc three standard antihypertens medic
global clinic studi renal denerv symplic spyral multi-
electrod renal denerv system patient uncontrol
hypertens absenc antihypertens medic spyral
spyral htn pivot trial part broader spyral htn global clinic
program multi-phas clinic studi strategi aim establish safeti
efficaci renal denerv lower blood pressur trial investig
blood pressur lower effect safeti renal denerv absenc
medic primari efficaci safeti endpoint trial blood
pressur three month incid major advers event one-month
transcathet mitral valv replac medtron intrepid tmvr
patient sever symptomat mitral regurgit apollo
apollo trial us fda approv trial rapidli enrol site activ
patient sever bicuspid aortic valv stenosi predict
risk mortal surgic aortic valv replac savr
object trial evalu procedur safeti efficaci
medtron tavr system patient bicuspid aortic anatomi sever aortic
stenosi low risk savr multicent prospect singl arm subject
treat tavr system subject follow-up conduct pre
 first db devic enabl sens brain signal use proprietari
 allow data-driven person stimul patient
 softwar upgrad platform allow continu innov improv
treatment time includ eventu close loop system
 full bodi mri condit system market
 vs current interstim ii
year batteri longev virtual loss capac time
 surescan lead full-bodi mri condit use interstim
micro futur implant interstim ii
stand alon cgm system guardian connect launch sugar iq
bluetooth connect caregiv alert wireless/over-the-air softwar
auto correct bolus simplifi meal manag hyperglycemia
new cgm system type
estim enrol particip random
earli data first patient enrol prospect
random sham-control spyral htn-on trial present
late-break clinic trial session europcr meet
commenc may pari franc
data first patient posit blood pressur
decreas significantli baselin month renal denerv
spyral htn pivot trial random sham-control studi
investig renal denerv procedur patient
site europ australia japan
 analyst day expect complet patient enrol
earli data patient present european societi cardiolog
esc investig found statist signific
clinic import blood pressur reduct patient treat
renal denerv across offic ambulatori systol
 januari expect potenti present spyral htn
pivot march depend bayesian analysi
analyst day expect fda approv beyond
apollo trial expect enrol patient random basi
either studi devic convent mitral valv surgeri
expect bicuspid data march
primari outcom measur all-caus mortal stroke reoper
reintervent cardiovascular hospit composit year
 januari receiv ce mark begin
expect spring us fda approv launch
 januari receiv ce mark start european launch
januari
 alreadi submit await us fda approv launch
use case data extrem condit present attd
februari madrid spain
us pivot trial present expect ada june
medtron plc sale y/i
